Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
Montagna E, Pagan E, Bagnardi V, Colleoni M, Cancello G, Munzone E, Dellapasqua S, Bianco N, Campennì G, Iorfida M, Mazza M, De Maio A, Veronesi P, Sangalli C, Scateni B, Pettini G, Pravettoni G, Mazzocco K, Galimberti V. Montagna E, et al. Among authors: cancello g. Breast Cancer Res Treat. 2020 Dec;184(3):783-795. doi: 10.1007/s10549-020-05900-2. Epub 2020 Sep 14. Breast Cancer Res Treat. 2020. PMID: 32929568
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M. Montagna E, et al. Among authors: cancello g. Clin Breast Cancer. 2012 Jun;12(3):207-14. doi: 10.1016/j.clbc.2012.03.008. Epub 2012 Apr 20. Clin Breast Cancer. 2012. PMID: 22520733 Clinical Trial.
Metronomic therapy and breast cancer: a systematic review.
Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M. Montagna E, et al. Among authors: cancello g. Cancer Treat Rev. 2014 Sep;40(8):942-50. doi: 10.1016/j.ctrv.2014.06.002. Epub 2014 Jun 18. Cancer Treat Rev. 2014. PMID: 24998489 Review.
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Cancello G, et al. Clin Breast Cancer. 2015 Aug;15(4):259-65. doi: 10.1016/j.clbc.2015.03.002. Epub 2015 Mar 18. Clin Breast Cancer. 2015. PMID: 25933934 Clinical Trial.
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26. Cancer Lett. 2017. PMID: 28131905 Clinical Trial.
Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
Palazzo A, Dellapasqua S, Munzone E, Bagnardi V, Mazza M, Cancello G, Ghisini R, Iorfida M, Montagna E, Goldhirsch A, Colleoni M. Palazzo A, et al. Among authors: cancello g. Clin Breast Cancer. 2018 Aug;18(4):328-335. doi: 10.1016/j.clbc.2018.01.010. Epub 2018 Feb 2. Clin Breast Cancer. 2018. PMID: 29486983 Clinical Trial.
45 results